Log In
Print
BCIQ
Print
Print this Print this
 

HDM-SPIRE, ToleroMune house dust mite therapy

  Manage Alerts
Collapse Summary General Information
Company Circassia Pharmaceuticals plc
DescriptionT cell vaccine against house dust mites using ToleroMune T cell epitope desensitization technology
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsTreat house dust mite allergy
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today